Impact of the primary information source used for decision making and implications for treatment regret in prostate cancer.

Authors

null

Narek Shaverdian

David Geffen School of Medicine at UCLA, Los Angeles, CA

Narek Shaverdian , Amar Upadhyaya Kishan , Darlene Veruttipong , D. Jeffrey Demanes , Patrick Kupelian , Susan Ann McCloskey , Michael L. Steinberg , Christopher R. King

Organizations

David Geffen School of Medicine at UCLA, Los Angeles, CA, University of California, Los Angeles, Los Angeles, CA, UCLA Radiation Oncology, Los Angeles, CA, Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, University of California Los Angeles Health Syst, Los Angeles, CA, NRG Oncology/NSABP, and UCLA, Santa Monica, CA, Department of Radiation Oncology, University of California, Los Angeles School of Medicine, Los Angeles, CA

Research Funding

Other

Background: Patients with localized prostate cancer (PCa) assimilate information from varying sources to inform their treatment decision. We assessed the impact of the primary information source used to select a modern radiation treatment on patient perceptions of their treatment experience and on treatment regret. Methods: Patients with favorable-risk PCa treated with SBRT, IMRT or HDR brachytherapy and at least one year of follow-up were surveyed. The questionnaire explored the decision-making experience, expected treatment experience vs. the reality, and treatment regret via a validated tool. Multivariate logistic regression adjusted for demographics, disease characteristics, treatment modality, time since treatment and current bowel, urinary and sexual function. Results: 322 consecutive patients were surveyed with an 86% (n = 276) response rate. 48% (n = 132) selected their radiation oncologist as the primary information source, 23% (n = 62) selected their urologist, 16% (n = 44) selected the internet, 6% (n = 17) selected other patients and 8% (n = 21) selected other. Overall, 13% (n = 36) endorsed treatment regret. 39% of patients who selected the internet as their primary information source reported their actual treatment experience to be worse than expected vs. 13% of respondents who selected their urologist, 12% who selected other patients, 2% who selected their radiation oncologist and 9% who selected other (p< 0.01). Similarly, 43% who selected the internet as their primary information source endorsed treatment regret vs. 10% who selected their urologist, 7% who selected their radiation oncologist, 6% who selected other patients and 6% who selected other (p< 0.01). On multivariate logistic regression, only patients who selected the internet as their primary information source were more likely to endorse treatment regret (OR = 46.5, p< 0.01) and were more likely to choose a treatment they thought ‘had the least side effects’ (OR = 2.1, p= 0.016). Conclusions: Patients who used the internet as their primary source of information had a worse perception of their treatment experience and had more treatment regret, highlighting the need for physicians to proactively counsel patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 17)

DOI

10.1200/JCO.2017.35.6_suppl.17

Abstract #

17

Poster Bd #

B4

Abstract Disclosures

Similar Abstracts

First Author: Daniel Eidelberg Spratt

Abstract

2023 ASCO Genitourinary Cancers Symposium

Randomized trial of five or two MRI-guided adaptive radiotherapy treatments for prostate cancer (FORT).

First Author: Ariel E. E. Marciscano

Abstract

2023 ASCO Genitourinary Cancers Symposium

Pelvic clinical node-positive prostate cancer: Impact of radiotherapy and nodal disease burden.

First Author: Tony Felefly